File Download

There are no files associated with this item.

Supplementary

Conference Paper: Chasing Ehrlich’s Magic Bullet – Nucleic acid aptamers for therapy and diagnostics

TitleChasing Ehrlich’s Magic Bullet – Nucleic acid aptamers for therapy and diagnostics
Authors
Issue Date2011
Citation
The Croucher Advanced Study Institute (ASI): Conference on Structure-Based Sreening and Design of Ligands for Protein Targets, The Chinese University of Hong Kong, Hong Kong, 12-15 December 2011 How to Cite?
AbstractHighly specific molecular recognition between nucleic acids and proteins is a fundamental tenet of life. Artificial selection of a nucleic acid, whereby a particular target‐binding nucleic acid is selected and evolved from a large unbiased random pool, was first achieved over 20 years ago. This process of in vitro molecular evolution towards the evolved nucleic acid aptamer was termed SELEX ‐ systematic evolution of ligands by exponential enrichment – and has had major impact over the last two decades in both basic and applied sciences. One particular application of such selected nucleic acids is in medicine, and aptamers have been clinically proven over recent years. Our laboratory has been developing aptamers as a new therapeutic approach against skeletal disease and tuberculosis. We have also been developing aptamers as perhaps a better and cheaper way to diagnose malaria. Here, we discuss our progress with a particular focus on the biochemistry of the nucleic acid‐protein molecular recognition events underpinning such potential medical applications.
DescriptionInvited Talk: paper no. S05
Persistent Identifierhttp://hdl.handle.net/10722/226216

 

DC FieldValueLanguage
dc.contributor.authorTanner, JA-
dc.date.accessioned2016-06-15T06:42:10Z-
dc.date.available2016-06-15T06:42:10Z-
dc.date.issued2011-
dc.identifier.citationThe Croucher Advanced Study Institute (ASI): Conference on Structure-Based Sreening and Design of Ligands for Protein Targets, The Chinese University of Hong Kong, Hong Kong, 12-15 December 2011-
dc.identifier.urihttp://hdl.handle.net/10722/226216-
dc.descriptionInvited Talk: paper no. S05-
dc.description.abstractHighly specific molecular recognition between nucleic acids and proteins is a fundamental tenet of life. Artificial selection of a nucleic acid, whereby a particular target‐binding nucleic acid is selected and evolved from a large unbiased random pool, was first achieved over 20 years ago. This process of in vitro molecular evolution towards the evolved nucleic acid aptamer was termed SELEX ‐ systematic evolution of ligands by exponential enrichment – and has had major impact over the last two decades in both basic and applied sciences. One particular application of such selected nucleic acids is in medicine, and aptamers have been clinically proven over recent years. Our laboratory has been developing aptamers as a new therapeutic approach against skeletal disease and tuberculosis. We have also been developing aptamers as perhaps a better and cheaper way to diagnose malaria. Here, we discuss our progress with a particular focus on the biochemistry of the nucleic acid‐protein molecular recognition events underpinning such potential medical applications.-
dc.languageeng-
dc.relation.ispartofCroucher ASI 2011-
dc.titleChasing Ehrlich’s Magic Bullet – Nucleic acid aptamers for therapy and diagnostics-
dc.typeConference_Paper-
dc.identifier.emailTanner, JA: jatanner@hku.hk-
dc.identifier.authorityTanner, JA=rp00495-
dc.identifier.hkuros198570-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats